Abbott To Assert New Biaxin XL Patent In Ongoing Suits
This article was originally published in The Pink Sheet Daily
Executive Summary
Abbott is asserting its new pharmacokinetic patent issued for Biaxin XL (clarithromycin extended-release) in ongoing litigation, the company said during its earnings call April 12